DPYSL2 and ovarian cancer: We next tested the functional consequences of Y479 phosphorylation in the ovarian cancer cell line OVCA432 using ectopic expression of the wild-type CRMP2, CRMP2-Y479E phosphomimetic mutant, or CRMP2-Y479F phosphorylation-resistant mutant.